Dr. Drilon on Entrectinib in Patients With Advanced Solid Tumors

Alexander Drilon, MD
Published: Monday, May 16, 2016



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses two studies investigating entrectinib in patients with advanced solid tumors.

Combined results were recently presented from the ALKA-372-001 study, which explored intermittent and continuous dosing of entrectinib, and the STARTRK-1 study, which looked at continuous dosing of the agent. In a safety analysis of 119 patients, entrectinib was found to be very well tolerated, Drilon says.

The majority of adverse events were grade 1/2 and included fatigue, changes in taste, and paresthesia. One of the longest responders enrolled on the study has been on treatment for 2 years and 3 months, Drilon adds.
 


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses two studies investigating entrectinib in patients with advanced solid tumors.

Combined results were recently presented from the ALKA-372-001 study, which explored intermittent and continuous dosing of entrectinib, and the STARTRK-1 study, which looked at continuous dosing of the agent. In a safety analysis of 119 patients, entrectinib was found to be very well tolerated, Drilon says.

The majority of adverse events were grade 1/2 and included fatigue, changes in taste, and paresthesia. One of the longest responders enrolled on the study has been on treatment for 2 years and 3 months, Drilon adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x